Intravitreal Dexamethasone in the Management of Delayed-Onset Bleb-Associated Endophthalmitis
Purpose. To report the visual acuity (VA) outcomes and culture results of delayed-onset bleb-associated endophthalmitis (BAE) with and without intravitreal dexamethasone (IVD). Methods. Retrospective nonrandomized comparative case series of BAE at Bascom Palmer Eye Institute between January 1, 1996...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | International Journal of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2012/503912 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832562701307478016 |
|---|---|
| author | David J. Jacobs Avinash Pathengay Harry W. Flynn Theodore Leng Darlene Miller Wei Shi |
| author_facet | David J. Jacobs Avinash Pathengay Harry W. Flynn Theodore Leng Darlene Miller Wei Shi |
| author_sort | David J. Jacobs |
| collection | DOAJ |
| description | Purpose. To report the visual acuity (VA) outcomes and culture results of delayed-onset bleb-associated endophthalmitis (BAE) with and without intravitreal dexamethasone (IVD). Methods. Retrospective nonrandomized comparative case series of BAE at Bascom Palmer Eye Institute between January 1, 1996 and December 31, 2009. Clinical data were compared using the 2-sided Student's t-test for patients who received IVD and patients who did not receive IVD. Results. 70/83 (84%) received IVD, and 13/83 (16%) did not receive IVD. Mean baseline VA was 20/90 in the IVD group and 20/70 in the group that did not receive IVD (P=0.57). Mean presenting VA was 0.9/200 in the IVD group and 1.7/200 in the group that did not receive IVD (P=0.23). Repeat cultures were positive in 2/70 (3%) IVD cases and 1/13 (8%) cases that did not receive IVD (P=0.57). Mean VA at 1 month was 5/200 in the IVD group and 1.8/200 in the group that did not receive IVD, logMARΔ of 0.85 and 1.56, respectively (P=0.02). Mean VA at 3 months was 7/200 in the IVD group and 3/200 in the group that did not receive IVD, logMARΔ of 0.74 and 1.33, respectively (P=0.14). Conclusion. In the current study of BAE, IVD was associated with improved short-term VA outcomes without an increased rate of persistent infection. |
| format | Article |
| id | doaj-art-d20d5b6bf9ad4364940f7b8ce8203031 |
| institution | Kabale University |
| issn | 2090-8040 2042-0099 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Inflammation |
| spelling | doaj-art-d20d5b6bf9ad4364940f7b8ce82030312025-02-03T01:22:02ZengWileyInternational Journal of Inflammation2090-80402042-00992012-01-01201210.1155/2012/503912503912Intravitreal Dexamethasone in the Management of Delayed-Onset Bleb-Associated EndophthalmitisDavid J. Jacobs0Avinash Pathengay1Harry W. Flynn2Theodore Leng3Darlene Miller4Wei Shi5Department of Ophthalmology, Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami, Miami, FL 33136, USADepartment of Ophthalmology, Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami, Miami, FL 33136, USADepartment of Ophthalmology, Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami, Miami, FL 33136, USADepartment of Ophthalmology, Byers Eye Institute at Stanford, Stanford School of Medicine, Palo Alto, CA 94303, USADepartment of Ophthalmology, Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami, Miami, FL 33136, USADepartment of Ophthalmology, Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami, Miami, FL 33136, USAPurpose. To report the visual acuity (VA) outcomes and culture results of delayed-onset bleb-associated endophthalmitis (BAE) with and without intravitreal dexamethasone (IVD). Methods. Retrospective nonrandomized comparative case series of BAE at Bascom Palmer Eye Institute between January 1, 1996 and December 31, 2009. Clinical data were compared using the 2-sided Student's t-test for patients who received IVD and patients who did not receive IVD. Results. 70/83 (84%) received IVD, and 13/83 (16%) did not receive IVD. Mean baseline VA was 20/90 in the IVD group and 20/70 in the group that did not receive IVD (P=0.57). Mean presenting VA was 0.9/200 in the IVD group and 1.7/200 in the group that did not receive IVD (P=0.23). Repeat cultures were positive in 2/70 (3%) IVD cases and 1/13 (8%) cases that did not receive IVD (P=0.57). Mean VA at 1 month was 5/200 in the IVD group and 1.8/200 in the group that did not receive IVD, logMARΔ of 0.85 and 1.56, respectively (P=0.02). Mean VA at 3 months was 7/200 in the IVD group and 3/200 in the group that did not receive IVD, logMARΔ of 0.74 and 1.33, respectively (P=0.14). Conclusion. In the current study of BAE, IVD was associated with improved short-term VA outcomes without an increased rate of persistent infection.http://dx.doi.org/10.1155/2012/503912 |
| spellingShingle | David J. Jacobs Avinash Pathengay Harry W. Flynn Theodore Leng Darlene Miller Wei Shi Intravitreal Dexamethasone in the Management of Delayed-Onset Bleb-Associated Endophthalmitis International Journal of Inflammation |
| title | Intravitreal Dexamethasone in the Management of Delayed-Onset Bleb-Associated Endophthalmitis |
| title_full | Intravitreal Dexamethasone in the Management of Delayed-Onset Bleb-Associated Endophthalmitis |
| title_fullStr | Intravitreal Dexamethasone in the Management of Delayed-Onset Bleb-Associated Endophthalmitis |
| title_full_unstemmed | Intravitreal Dexamethasone in the Management of Delayed-Onset Bleb-Associated Endophthalmitis |
| title_short | Intravitreal Dexamethasone in the Management of Delayed-Onset Bleb-Associated Endophthalmitis |
| title_sort | intravitreal dexamethasone in the management of delayed onset bleb associated endophthalmitis |
| url | http://dx.doi.org/10.1155/2012/503912 |
| work_keys_str_mv | AT davidjjacobs intravitrealdexamethasoneinthemanagementofdelayedonsetblebassociatedendophthalmitis AT avinashpathengay intravitrealdexamethasoneinthemanagementofdelayedonsetblebassociatedendophthalmitis AT harrywflynn intravitrealdexamethasoneinthemanagementofdelayedonsetblebassociatedendophthalmitis AT theodoreleng intravitrealdexamethasoneinthemanagementofdelayedonsetblebassociatedendophthalmitis AT darlenemiller intravitrealdexamethasoneinthemanagementofdelayedonsetblebassociatedendophthalmitis AT weishi intravitrealdexamethasoneinthemanagementofdelayedonsetblebassociatedendophthalmitis |